SNDX · Syndax Pharmaceuticals, Inc.
$13.40
-1.25% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-16.0
Dividend yield
0.0%
Beta
0.42
Avg volume
2M
Employees
0K
Daily Change %
-1.25%
5 Days Change
5.19%
10 Days Change
-2.72%
30 Days Change
-23.07%
60 Days Change
-30.66%
Month to Day Change
-25.52%
Year to Day Change
-35.41%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SNDX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-13
Latest call per bank · past 12 months
UBS
Buy$33.00
+146.3% vs priceJP Morgan
Overweight$40.00
+198.5% vs priceBarclays
Overweight$37.00
+176.1% vs priceGoldman Sachs
Buy$34.00
+153.7% vs priceCitigroup
Buy$57.00
+325.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | HC Wainwright & Co. | Reiterates | Buy | $38.00 |
| 2026-08-21 | UBS | Maintains | Buy | $37.00 → $33.00 |
| 2026-08-11 | JP Morgan | Maintains | Overweight | $44.00 → $40.00 |
| 2026-08-05 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $38.00 |
| 2026-07-15 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-06-12 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-05-22 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-05-13 | UBS | Maintains | Buy | $38.00 → $37.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 28 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 24.7% below the 50-day MA ($17.80).
- bearish: Price vs 200-day MA: Trading 34.4% below the 200-day MA ($20.41).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.17) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($12.90).
SNDX Price Chart
Loading chart for SNDX…
Fundamentals
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.